What We're Reading: Page 165
Industry reads hand-picked by our editors
Apr 28, 2021
-
The New York Times
How Europe Sealed a Pfizer Vaccine Deal With Texts and Calls
-
Endpoints News
Ohana, Flagship's big bet on fertility treatments, shuts down and lays off staff after VC pulls the plug
-
STAT
A shortage of tiny pipette tips is creating huge problems for science
-
Financial Times
GSK chief defends against accusations of flat performance
Apr 27, 2021
-
The Wall Street Journal
Prescription-Drug Price Cuts Set to Be Left Out of White House Proposal
-
Associated Press
US to share AstraZeneca shots with world after safety check
-
Reuters
Top U.S. trade negotiator meets Pfizer, AstraZeneca execs on COVID-19 IP waiver
-
Evaluate Vantage
Zolgensma flatlines, but Spinraza isn't the beneficiary
Apr 26, 2021
-
Bloomberg
The First Billion Doses
-
FiercePharma
ADC Therapeutics scores FDA approval for anti-CD19 blood cancer med Zynlonta
-
The Washington Post
Vaccine maker Emergent's CEO sold $10 million in stock before company ruined Johnson & Johnson doses
-
Evaluate Vantage
Bristol's Tyk2 ticks the boxes
Apr 23, 2021
-
The New York Times
With Few New Clotting Cases, Johnson & Johnson Pause Could Be Lifted Soon
-
Life Sci VC
Five Macro Risks To Biotech Coming Out of Washington | LifeSciVC
-
The Financial Times
Scientists split over advice on giving AstraZeneca jab to UK under-40s
Apr 22, 2021
-
The Wall Street Journal
Biotech Stocks Fall Out of Favor After Disappointing Trial Results, Big Rally
-
Endpoints News
As fears mount over J&J and AstraZeneca, Novavax enters a shaky spotlight
-
Bloomberg
Pfizer to Place 100 Young Minorities in New Fellowship Program
-
MIT Technology Review
New preconception testing could predict your child's risk to common diseases
Apr 21, 2021
Apr 20, 2021
-
Fortune
This biotech startup thinks it can delay menopause by 15 years. That would transform women’s lives
-
Chemical & Engineering News
Making stem cell transplants safer
-
STAT
Genetically targeted drug from Syndax Pharma shows remissions in leukemia patients
-
The New York Times
Emergent BioSolutions halts operations at its Baltimore plant, where J.&J. doses were ruined, at the F.D.A.’s request.
Previous
